Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $215.90 | Total: $1,079.50 |
| 1 | 10 | $182.88 | Total: $1,828.80 |
| 1 | 25 | $154.94 | Total: $3,873.50 |
| 1 | 50 | $132.08 | Total: $6,604.00 |
| 1 | 100 | $114.30 | Total: $11,430.01 |
Overview
EZM0414 TFA (SETD2-IN-1 TFA) is a SETD2 inhibitor with anticancer and antiproliferative effects for the study of leukemia and immune dysfunction.
Chemical Properties
| Molecular Formula | C24H30F4N4O4 |
| Molecular Weight | 514.51 |
| CAS Numbers | 2411759-92-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | OC(=O)C(F)(F)F.CC(=O)N1CCN(CC1)[C@H]1CCC[C@H](C1)NC(=O)c1cc2c(F)ccc(C)c2[nH]1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Alford JS,et al. Conformational-Design-Driven Discovery of EZM0414 A Selective, Potent SETD2 Inhibitor for Clinical Studies. ACS Med Chem Lett. 2022 Jun 7;13[7] 1137-1143.